Completed PHASE1 INTERVENTIONAL 2-arm NCT00653003

Bioavailability Study of Leflunomide Tablets Under Fed Conditions

To Compare the Relative Bioavailability of Leflunomide 20mg Tablets (Kali) With That of ARAVA 20mg Tablets(Aventis) Under Fed Conditions

Sponsor: Novum Pharmaceutical Research Services

Conditions To Determine Bioequivalence Under Fed Conditions

Interventions ARAVA Leflunomide

Updated 7 times since 2017 Last updated: Sep 22, 2017 Started: Dec 31, 2003 Primary completion: Jan 31, 2004 Completion: Jan 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00653003, this PHASE1 trial focuses on To Determine Bioequivalence Under Fed Conditions and remains completed. Sponsored by Novum Pharmaceutical Research Services, it has been updated 7 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Oct 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Oct 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novum Pharmaceutical Research Services
Par Pharmaceutical, Inc.

Data source: Par Pharmaceutical, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.